Irreversible electroporation for prostate cancer using PSMA PET-CT

Shin, Dong–Ho; Yoon, Chang Eil; Kwon, Hyeok Jae; Moon, Hyong Woo; Park, Yong Hyun; Cho, Hyuk Jin; Ha, U-Syn; Hong, Sung‐Hoo; Park, Sonya Youngju; Ha, Seunggyun; O, Joo Hyun; Yoo, Ie Ryung; Park, Chansoo; Lee, Ji Youl

doi:10.1016/j.prnil.2022.08.004

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSMA-specific ligands for PET imaging are frequently labeled with radioactive isotopes, such as 68 Ga and 18 F. The diagnostic radioisotope 68 Ga exhibits a relatively short half-life of 68 min and is produced from either 68 Ge/ 68 Ga-generator or cyclotron [7]. Conversely, 18 F-labeled PSMA compounds exhibit a relatively long half-life of 110 min and are produced in a cyclotron [8][9][10][11][12][13][14]. 64 Cu constitutes another diagnostic radioisotope.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background: This study compared the effects of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) as 64Cu-chelating agents in newly developed prostate-specific membrane antigen (PSMA) target compounds, 64Cu-cudotadipep and 64Cu-cunotadipep, on pharmacokinetics. Methods: The in vitro stability of the chelators was evaluated using human and mouse serum. In vitro PSMA-binding affinity and cell uptake were compared using human 22Rv1 cells. To evaluate specific PSMA-expressing tumor-targeting efficiency, micro-positron emission tomography (mcroPET)/computed tomography (CT) and biodistribution analysis were performed using PSMA+ PC3-PIP and PSMA− PC3-flu tumor xenografts. Results: The serum stability of DOTA- or NOTA-conjugated 64Cu-cudotadipep and 64Cu-cunotadipep was >97%. The Ki value of the NOTA derivative, cunotadipep, in the in vitro affinity binding analysis was higher (2.17 ± 0.25 nM) than that of the DOTA derivative, cudotadipep (6.75 ± 0.42 nM). The cunotadipep exhibited a higher cellular uptake (6.02 ± 0.05%/1 × 106 cells) compared with the cudotadipep (2.93 ± 0.06%/1 × 106 cells). In the biodistribution analysis and microPET/CT imaging, the 64Cu-labeled NOTA derivative, 64Cu-cunotadipep, demonstrated a greater tumor uptake and lower liver uptake than the DOTA derivative. Conclusions: This study indicates that the PSMA-targeted 64Cu-cunotadipep can be applied in clinical practice owing to its high diagnostic power for prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, various imaging modalities have been utilised to assess tumour response, such as multiparametric MRI (mpMRI) [ 56 ], contrast-enhanced ultrasound (CEUS) [ 57 ], and prostate-specific membrane antigen (PSMA) positron emission tomography—CT (PET-CT) [ 58 ]. Nevertheless, tissue biopsy remains the gold standard for accurately evaluating tumour response or recurrence.…”

Section: Irreversible Electroporationmentioning

confidence: 99%

Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation

Campana

Daud

Lancellotti

et al. 2023

Cancers

View full text Add to dashboard Cite

The 4th World Congress of Electroporation (Copenhagen, 9–13 October 2022) provided a unique opportunity to convene leading experts in pulsed electric fields (PEF). PEF-based therapies harness electric fields to produce therapeutically useful effects on cancers and represent a valuable option for a variety of patients. As such, irreversible electroporation (IRE), gene electrotransfer (GET), electrochemotherapy (ECT), calcium electroporation (Ca-EP), and tumour-treating fields (TTF) are on the rise. Still, their full therapeutic potential remains underappreciated, and the field faces fragmentation, as shown by parallel maturation and differences in the stages of development and regulatory approval worldwide. This narrative review provides a glimpse of PEF-based techniques, including key mechanisms, clinical indications, and advances in therapy; finally, it offers insights into current research directions. By highlighting a common ground, the authors aim to break silos, strengthen cross-functional collaboration, and pave the way to novel possibilities for intervention. Intriguingly, beyond their peculiar mechanism of action, PEF-based therapies share technical interconnections and multifaceted biological effects (e.g., vascular, immunological) worth exploiting in combinatorial strategies.

show abstract

Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis

Ahn

Hwang

Lee

et al. 2023

Prostate International

View full text Add to dashboard Cite

Irreversible electroporation for prostate cancer using PSMA PET-CT

Cited by 4 publications

References 31 publications

Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer

Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer

Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation

Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis

Contact Info

Product

Resources

About